⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182923 | 1.00 | — | — | |
| SCHEMBL12292174 | 1.00 | — | — | |
| SCHEMBL183142 | 1.00 | — | — | |
| SCHEMBL4324438 | 1.00 | — | — | |
| SCHEMBL30613700 | 1.00 | — | — | |
| SCHEMBL18534632 | 1.00 | — | — | |
| SCHEMBL182886 | 1.00 | — | — | |
| SCHEMBL16566052 | 1.00 | — | — | |
| SCHEMBL182922 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1775572 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628488-A1 | CYCLIN K DEGRADER AND USE THEREOF | Adlai Nortye Biopharma Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12312336-B2 | Inhibitors of RAF kinases | Pierre Fabre Médicament (FR) | 2025-05-27 | — | — | US | disclosed |
| US-20240368147-A1 | CYCLIN K DEGRADER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| CN-114845711-B | Inhibitors of RAF kinase | 皮埃尔法布雷医药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240317775-A1 | H4 Antagonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-20240270740-A1 | INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2024125551-A1 | CYCLIN K DEGRADER AND USE THEREOF | 杭州阿诺生物医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-118206535-A | Cyclin K degrading agent and application thereof | 杭州阿诺生物医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4382519-A1 | CYCLIN K DEGRADATION AGENT | Adlai Nortye Biopharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240150361-A1 | IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS | BEIGENE, LTD. (KY) | 2024-05-09 | — | — | US | disclosed |
| EP-1939185-A1 | New types of hetaryl-phenylendiamin-pyrimidines as protein kinase inhibitors for the treatment of cancer | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074515-A1 | NOVEL HETARYL-PHENYLENE-DIAMINE PYRIMIDINE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
| US-20070292927-A1 | producing 2-butanol and 2-butanone by the fermentive growth of a recombinant bacteria expressing a 2-butanol biosynthetic pathway | GEVO, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007130521-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130518-A2 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259410-A1 | FERMENTIVE PRODUCTION OF FOUR CARBON ALCOHOLS | GEVO, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007110649-A2 | PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES | CYCLACEL LIMITED (GB) | 2007-10-04 | — | — | WO | disclosed |